Related Experiment Videos
Vaccinoprophylaxis of mumps using mumps vaccine, strain Sofia 6, in Bulgaria
1Department of Virology and Epidemiology, Sofia, Bulgaria.
Vaccine
|November 1, 1994
Insights
Bulgaria
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Mumps vaccine, strain Sofia 6, was used in Bulgaria from 1972.
- Included in the national program in 1977 for children aged 1-12.
- Initial vaccine showed good immunogenicity and efficacy.
Purpose of the Study:
- Evaluate the long-term efficacy and safety of the mumps vaccine.
- Assess the impact of revaccination on mumps morbidity.
- Document vaccine-related adverse events.
Main Methods:
- Longitudinal study of mumps vaccination in Bulgarian children (1972-1982).
- Monitoring of vaccine efficacy, immunogenicity, and reactogenicity.
- Analysis of side-effects, particularly meningitis, post-revaccination.
Main Results:
- The mumps vaccine demonstrated high epidemiological efficacy and good immunogenicity.
- A slight reactogenicity was observed.
- Revaccination in 1982 led to a high incidence of side-effects, including meningitis.
Conclusions:
- The mumps vaccine was initially effective but associated with significant adverse events.
- A high rate of meningitis following revaccination led to its suspension.
- This highlights the importance of ongoing vaccine safety surveillance.
Abstract:
A mumps vaccine, using strain Sofia 6 prepared in guinea-pig kidney primary cell cultures, was gradually introduced in Bulgaria to vaccinate 1- to 12-year-old children between 1972 and 1976. It was included in the national vaccine programme in 1977. The vaccine showed a slight reactogenicity, a good immunogenicity and a high epidemiological efficacy. Due to the increased morbidity of mumps, revaccination was carried out in 4- to 12-year-old children in 1982. A high level of side-effects, mainly meningitis, was registered, and led to suspension of the mumps vaccine in Bulgaria.